ReviewMolecular biology reports2026
Anticancer properties of Artemisia species: mechanisms and experimental evidence.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Artemisia (family Asteraceae) is widely recognized for its medicinal properties, among which artemisinin is the most notable, historically serving as a key antimalarial agent. Accumulating evidence now highlights the significant anticancer potential of Artemisia species, with bioactive compounds such as artemisinin and its derivatives exhibiting promising activity across multiple cancer types. This review provides a comprehensive overview of the molecular mechanisms underlying the anticancer effects of Artemisia-derived compounds, including apoptosis induction, cell cycle arrest, and oxidative stress modulation. In addition, it examines their therapeutic efficacy in preclinical in vivo models and summarizes findings from early-phase clinical trials. Despite encouraging preclinical results, challenges such as drug resistance, limited bioavailability, and barriers to clinical translation remain.
Indexed as
Identifiers
41860671What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.